DNA scriptThe pioneer of enzymatic DNA synthesis (EDS) for on-demand DNA printing, recently announced the completion of its Series C financing, raising US$200 million in new funding. Through the latest round of financing, DNA Script has raised US$315 million since its establishment in 2014.
The accounts and funds consulted by T. Rowe Price Associates and Baillie Gifford joined Healthcor Management, eureKARE and Irving Investors in the second batch of the C series. They joined Coatue Management, Catalonia Capital Management, Fidelity Management & Research Company LLC, Columbia Threadneedle Investments, Casdin Capital and other investors participating in the first settlement.
The proceeds from this financing will be used to advance the SYNTAX platform, which is DNA Script’s first commercial product supported by its proprietary EDS technology. SYNTAX enables scientists to conveniently and quickly print synthetic nucleic acids for genomics and molecular biology applications on the laboratory bench. On-demand printing allows laboratories to receive genetic material from third-party service providers for iteration without waiting days or weeks.
“We are delighted to work with this world-class investor, including new participants Baillie Gifford and T. Rowe Price, who shared our vision of increasing opportunities for oligonucleotide manufacturing to accelerate the biological revolution,” DNA Thomas Ebert, Co-founder and CEO of Script. “SYNTAX is the first step in creating a new paradigm for DNA and RNA synthesis. With the support of our investors, we look forward to continuing to advance this new paradigm to solve some of our biggest challenges and promote human health.”
To read more, click here.
Skin biotin, A clinical-stage biotechnology company that develops targeted topical therapies for the underlying causes of skin diseases has raised $28 million in Series A2 financing and announced the acquisition of clinical-stage biotechnology company Chromaderm, which is developing a local melanin production inhibitor , As the first class treatment for skin whitening, chloasma and other skin diseases. As part of these new developments, they appointed Dr. Emma Taylor as Chief Medical Officer. Dr. Taylor, a dermatologist certified by the board of directors.
“We are very happy to welcome Chromaderm and his team to DermBiont,” said Dr. Karl Beutner, co-founder and CEO of DermBiont. “The topical small molecule drugs being developed by Chromaderm are very suitable for DermBiont’s product portfolio, which focuses on targeted topical treatment of skin diseases with a clear mechanism of action.”
Excessive melanin production is the root cause of many common skin diseases, including melasma, sun-induced freckles (dark spots), and hyperpigmentation after inflammation. These diseases are most common among Hispanics, African Americans and Asians, and mainly affect women; Melasma affects approximately 5 million people in the United States, and the prevalence in some populations is as high as 40%. The current treatment effect for these diseases is very small, not specific, and there are major safety issues.
As part of the transaction, Jeni Lee, head of Pivotal Life Sciences, joined DermBiont’s board of directors. In addition to Pivotal Life Sciences, this round of financing also includes participation from Viking Global Investors, Olive Tree Capital, Toba Capital, Civilization Ventures and other biotech investors.
To read more, click here.
The regulatory structure of rewards and incentives in Medicare Advantage has officially changed. If you need help in the new guidelines effective January 1, 21, Healthy mine The most frequently asked questions we have received have been compiled into a convenient FAQ document.
To check, click here.
Bamboo health, Formerly Appriss Health and PatientPing, a health technology company that supports nursing collaborations and provides information and actionable healthcare insights, has appointed President and General Manager Rob Cohen as CEO.
To read more, click here.
picture: Aquindo, Getty Images
